Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Björn Tackenberg

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|December 23, 2019
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumabTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Therapeutic Advances in Neurological Disorders|May 1, 2018
Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)Ralf Gold, Eugen Schlegel, Birte Elias-Hamp, et al.
Health and Quality of Life Outcomes|October 5, 2013
Preference-based Health status in a German outpatient cohort with multiple sclerosisJens Peter Reese, Gabriele Wienemann, Axel John, et al.
Journal of Neurology|December 26, 2012
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJoachim Havla, Björn Tackenberg, Kerstin Hellwig, et al.
Plos One|May 2, 2020
Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims dataChristoph Ohlmeier, Holger Gothe, Judith Haas, et al.
Muscle & Nerve|August 4, 2018
Costs of illness in chronic inflammatory demyelinating polyneuropathy in GermanyDavid Mengel, Linda Fraune, Norbert Sommer, et al.
Gene|August 9, 2020
Alternative splicing of the TNFSF13B (BAFF) pre-mRNA and expression of the BAFFX1 isoform in human immune cellsPatrick Stelmach, Michael Pütz, Robert Pollmann, et al.
Brain, Behavior, and Immunity|October 28, 2010
Interictal alterations of cytokines and leukocytes in patients with active epilepsyMareike Nowak, Sebastian Bauer, Anja Haag, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 19, 2019
Real-world persistence and benefit-risk profile of fingolimod over 36 months in GermanyTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2017
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MSVinzenz Fleischer, Michaela Friedrich, Ayman Rezk, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|December 23, 2019
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumabTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Therapeutic Advances in Neurological Disorders|May 1, 2018
Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)Ralf Gold, Eugen Schlegel, Birte Elias-Hamp, et al.
Health and Quality of Life Outcomes|October 5, 2013
Preference-based Health status in a German outpatient cohort with multiple sclerosisJens Peter Reese, Gabriele Wienemann, Axel John, et al.
Journal of Neurology|December 26, 2012
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJoachim Havla, Björn Tackenberg, Kerstin Hellwig, et al.
Plos One|May 2, 2020
Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims dataChristoph Ohlmeier, Holger Gothe, Judith Haas, et al.
Muscle & Nerve|August 4, 2018
Costs of illness in chronic inflammatory demyelinating polyneuropathy in GermanyDavid Mengel, Linda Fraune, Norbert Sommer, et al.
Gene|August 9, 2020
Alternative splicing of the TNFSF13B (BAFF) pre-mRNA and expression of the BAFFX1 isoform in human immune cellsPatrick Stelmach, Michael Pütz, Robert Pollmann, et al.
Brain, Behavior, and Immunity|October 28, 2010
Interictal alterations of cytokines and leukocytes in patients with active epilepsyMareike Nowak, Sebastian Bauer, Anja Haag, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 19, 2019
Real-world persistence and benefit-risk profile of fingolimod over 36 months in GermanyTjalf Ziemssen, Michael Lang, Björn Tackenberg, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2017
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MSVinzenz Fleischer, Michaela Friedrich, Ayman Rezk, et al.
Pageof 9